ClinicalTrials.gg
CompletedNCT06686797Updated Sep 8, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

A Phase 1 interventional study of PF-08049820 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
31st of 47
71 · median 121
Started
2024
with 2 others
Phase 1
13 of 58
1 open now
Registered
48th of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 31st largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2024, is one of 13 in phase 1, and was the 48th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see:

  • how the body processes the study medicine and
  • if food affects the amount of study medicine in the blood.

The study medicine is developed for the treatment of moderate to severe atopic dermatitis, also known as eczema. People with this condition may have severe itching and rashes on the skin.

The study is seeking participants who:

  1. Are males or females who can no longer have children,
  2. Are 18 to 65 years old,
  3. Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).

    For group or cohort 3 only:

  4. Have 4 biological Japanese grandparents who were born in Japan.

The study has three parts: Part A, Part B and Part C.

Part A consists of 3 groups (also known as "cohorts"). In Cohorts 1 and 2, there may be up to four dosing periods. During each dosing period, participants will take a single dose of the study medicine or placebo as liquid by mouth with or without food at the study clinic. A placebo does not have any medicine in it but looks just like the medicine being studied. The participants will stay at the study clinic for about 8 days and then can go home. During this time, the study team will observe the participants and take some urine and blood samples to test the level of the study medicine. The participants will return to the study clinic up to three more times to complete up to four dosing periods separated by at least 2 weeks. The participants will take increasing amounts of study medicine during each dosing period. After completion of the final dosing period, the participants will receive a follow-up telephone call about a month later. Cohort 3 consists of one dosing period and will enroll participants who have 4 biological Japanese grandparents who were born in Japan. Participants will be checked as described above and will receive a follow-up telephone call about one month after the last dose of study medicine or placebo.

Part B has 4 cohorts (Cohorts 4 to 7), each consisting of one dosing period. In all cohorts, participants will take multiple doses of the study medicine or placebo as tablets by mouth at the study clinic. Part C has two cohorts (Cohort 8 and 9), each consisting of one dosing period. In both cohorts, participants will take a single dose of the study medicine or placebo as tablets by mouth at the study clinic. Participants will be checked as described above and will receive a follow-up telephone call about one month after the last dose of study medicine or placebo.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females who can no longer have children.
  2. (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.). Japanese participants only: a total body weight >45 kg is acceptable.

    Cohort 3 only:

  3. Have 4 biological Japanese grandparents who were born in Japan

Exclusion criteria

Exclusion criteria

  1. Evidence or history of medical conditions.
  2. History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb).
  3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  4. Participation in studies of other products (drug or vaccine) at any time during their participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1

    Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part A: Cohort 2

    Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part A: Cohort 3

    One dosing period with a single dose of PF-08049820 or placebo in healthy adult Japanese participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part B: Cohort 4

    One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part B: Cohort 5

    One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part B: Cohort 6

    One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part B: Cohort 7

    One dosing period with multiple doses of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part C: Cohort 8

    One dosing period with a single dose of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

  • Experimental
    Part C: Cohort 9

    One dosing period with a single dose of PF-08049820 or placebo in healthy adult participants.

    Drug: PF-08049820 · Drug: Placebo

Interventions

  • Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Parts B and C (Cohorts 4 to 9).

  • DrugPlacebo

    Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Parts B and C (Cohorts 4 to 9).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B

  2. Number of Participants With Serious Adverse Events (SAEs)

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B

Secondary outcomes

  1. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    Part A (Cohorts 1 to 3) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 8 of last dosing period for Parts A and C

  2. Area under the curve from time zero to end of dosing interval (AUCtau)

    Part B (Cohorts 4 to 7)

    Time frame: Baseline up to Day 13 for Part B

  3. Maximum observed plasma concentration (Cmax)

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B

  4. Time to reach maximum observed plasma concentration (Tmax)

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B

  5. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B

  6. Plasma decay half-life (t1/2) if data permit

    Part A (Cohorts 1 to 3) Part B (Cohorts 4 to 7) Part C (Cohorts 8 and 9)

    Time frame: Baseline up to Day 8 of last dosing period for Parts A and C and up to Day 13 for Part B

  7. Amount of unchanged drug recovered in urine during dosing interval (Aetau)

    Part B (Cohorts 4 to 7)

    Time frame: Baseline up to Day 10 for Part B

  8. Percent of dose recovered in urine as unchanged drug over dosing interval (Aetau%)

    Part B (Cohorts 4 to 7)

    Time frame: Baseline up to Day 10 for Part B

  9. Renal clearance (CLr)

    Part B (Cohorts 4 to 7)

    Time frame: Baseline up to Day 10 for Part B

07

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Feb 2026, 14 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartActual
Nov 27, 2024
Primary completionActual
Feb 23, 2026
CompletionActual
Feb 23, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686797
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Nov 27, 2024
Primary completion
Feb 23, 2026
Completion
Feb 23, 2026
Last update
Sep 8, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-08049820

Start the discussion